# Anteris Technologies Global Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Anteris Technologies Global Corp.). ## Overview Anteris Technologies Global Corp. is a development-stage structural heart company focused on designing and commercializing the DurAVR® transcatheter heart valve system for patients with aortic stenosis. The company’s core technology is its proprietary ADAPT® anti-calcification tissue platform, which it is using to build a single-piece, biomimetic valve intended to improve durability and performance. In addition to its lead clinical program, Anteris has historically generated limited revenue from regenerative tissue products such as CardioCel™ and VascuCel™, mainly through supply arrangements with 4C Medical Technologies and LeMaitre Vascular. The business is still pre-commercial for its lead product and is spending heavily on clinical trials, manufacturing scale-up, and regulatory work to support the PARADIGM Trial and eventual FDA approval. ## Products & services • DurAVR® THV system • ADAPT® anti-calcification tissue • CardioCel™ regenerative tissue patches • VascuCel™ vascular patches • PARADIGM Trial clinical development • Manufacturing and supply of regenerative tissue products - **Structural heart / transcatheter valve system** (0%) — Lead development program for the DurAVR® THV system, a single-piece transcatheter aortic valve for aortic stenosis. - **Regenerative tissue products** (100%) — Commercial sales of CardioCel™ and VascuCel™ patches and related tissue products sold under supply arrangements. - **Proprietary tissue platform** (0%) — ADAPT® anti-calcification tissue technology used as the core biomaterial platform for the company’s valve and tissue products. - **Clinical and regulatory development** (0%) — Clinical trial execution, site qualification, IDE/PMA work, and manufacturing readiness for the PARADIGM Trial. - DurAVR® THV system - ADAPT® anti-calcification tissue - CardioCel™ regenerative tissue patches - VascuCel™ vascular patches - PARADIGM Trial clinical development - Manufacturing and supply of regenerative tissue products ## Customers Anteris currently sells regenerative tissue products primarily to medical-device companies and distributors rather than directly to hospitals or physicians. The company states that its current revenue comes mainly from 4C Medical Technologies and LeMaitre Vascular, which purchase tissue products under supply and license or transition arrangements. For the lead DurAVR® THV system, the eventual customers are expected to be interventional cardiologists, hospitals, and structural heart programs once regulatory approval is obtained and commercialization begins. The company is also working with trial sites in the U.S., Europe, and Canada, so clinical investigators and hospital-based trial centers are a critical near-term customer-like constituency for its development activities. - **Medical-device OEM partner** (primary) — 4C Medical Technologies purchases regenerative tissue products under a supply and license arrangement to support its own device programs. - **Distributor / channel partner** (primary) — LeMaitre Vascular historically bought and distributed CardioCel™ and VascuCel™ patches, providing commercial revenue from tissue products. - **Clinical trial sites** (primary) — Hospitals and centers in the U.S., Europe, and Canada qualify for and participate in the PARADIGM Trial, enabling product validation and regulatory progress. - **Future hospital and physician users** (secondary) — Structural heart programs and interventional cardiologists are the eventual buyers/users of DurAVR® once the product is approved and commercialized. - 4C Medical Technologies, which buys regenerative tissue under a supply/license agreement - LeMaitre Vascular, which previously distributed CardioCel™ and VascuCel™ - Clinical trial sites and investigators supporting PARADIGM enrollment - Hospitals and structural heart centers expected to adopt DurAVR® after approval - Interventional cardiologists who will evaluate and implant the valve system - Medical-device distributors that can extend reach for tissue products ## Geography Anteris is headquartered in the United States and is building its lead clinical program around trial sites across the U.S., Europe, and Canada. The company also has a meaningful operational footprint in Australia, where it has historically benefited from R&D tax incentive payments tied to qualifying development work. Its current commercial revenue base is limited and concentrated in supply relationships rather than broad geographic sales, so geography matters more for clinical execution and manufacturing readiness than for revenue diversification. The multinational trial footprint is important because PARADIGM site qualification, contracting, and regulatory coordination must be managed across several healthcare systems and approval environments. - United States is the corporate base and a key market for the PARADIGM Trial - Europe is part of the planned trial footprint and future commercialization pathway - Canada is included among qualified trial regions for PARADIGM - Australia is important for R&D activity and tax incentive support - Revenue is currently concentrated in limited supply relationships rather than broad country sales - Geographic execution risk is driven by multi-country clinical and regulatory coordination ## Strategy Anteris’ strategy is centered on completing the PARADIGM Trial and advancing the DurAVR® THV system through FDA review toward PMA approval. In parallel, the company is scaling manufacturing and clinical infrastructure so it can support trial inventory, process validation, and eventual commercial launch. Because the business remains pre-commercial for its lead product, capital preservation and financing are also strategic priorities, with management explicitly planning to raise additional equity or other securities. The company is using its existing regenerative tissue business and R&D tax incentives as bridge sources of funding while it pursues long-term value creation in structural heart therapy. - **Complete PARADIGM Trial execution** (short-term) — Clinical success is the main gate to FDA PMA and future commercialization of DurAVR®. - **Scale manufacturing readiness** (short-term) — The company must produce trial inventory and later commercial supply reliably to support regulatory and market adoption. - **Secure additional capital** (short-term) — Current cash is not expected to fund operations for 12 months, so financing is required to continue development. - **Transition from development to commercialization** (medium-term) — Long-term value depends on obtaining approval and converting clinical progress into product sales. - Advance the PARADIGM Trial to generate clinical evidence for DurAVR® - Maintain FDA IDE and pursue PMA approval for the lead valve system - Scale manufacturing and process validation ahead of trial and launch demand - Use existing tissue-product sales as bridge revenue while the valve program matures - Preserve liquidity through external financing and capital raises - Build clinical and regulatory infrastructure across the U.S., Europe, and Canada ## Risks The company faces substantial execution risk because its lead product is still in clinical development and depends on successful PARADIGM Trial outcomes and FDA PMA approval. Regulatory risk is especially important: the IDE could be revoked, the trial could fail, or post-market requirements could become expensive and burdensome even if approval is obtained. As a development-stage medtech company, Anteris also has material financing risk because it expects to need additional capital and does not expect significant revenue until commercialization begins. More broadly, structural heart companies face clinical adoption risk, manufacturing scale-up risk, reimbursement uncertainty, and the possibility that competing valve technologies or trial results reduce physician interest in the product. - **Clinical trial failure** [critical] — DurAVR® depends on PARADIGM Trial success to support regulatory approval and commercialization. - **Regulatory approval risk** [critical] — The FDA could delay, deny, or revoke IDE/PMA status, preventing market entry. - **Financing and dilution risk** [high] — The company expects to need additional capital and may rely on equity issuance or debt. - **Manufacturing scale-up risk** [high] — Trial and future commercial supply depend on successful process validation and inventory build. - **Commercial adoption risk** [medium] — Even with approval, physicians and hospitals may adopt the product slowly if evidence or economics are not compelling. - PARADIGM Trial may fail to demonstrate safety or efficacy - FDA IDE or PMA approval may be delayed, denied, or revoked - Additional post-market testing could raise costs after approval - Liquidity risk is high because current cash does not fund 12 months - Future equity raises may dilute shareholders or be unavailable on favorable terms - Manufacturing scale-up could create quality, yield, or supply issues - Clinical adoption may be slower than expected even if approved ## Accounting Anteris is a development-stage company, so reported results are heavily affected by judgmental estimates and the timing of development spending rather than stable product revenue. Revenue recognition is concentrated in a small number of supply arrangements, mainly with 4C Medical Technologies and previously LeMaitre Vascular, so changes in contract terms or expiration of transition services can materially affect quarterly revenue. The company also recognizes other income from Australian R&D tax incentive payments, which depend on qualifying expenditure and regulatory criteria, making the timing and amount of this support variable. Lease accounting and purchase commitments matter because the company leases laboratory and office facilities and has ongoing property obligations, while consolidation of variable interest entities requires judgment over control and economic interest. Investors should also watch for impairment or valuation issues tied to capitalized development assets, though the excerpts mainly indicate expensed R&D and ongoing losses rather than large amortizable commercial assets. - **Revenue recognition on supply contracts** — Quarterly revenue volatility - **Australian R&D tax incentive income** — Non-operating income variability - **Lease accounting** — Balance sheet obligations and liquidity analysis - **VIE consolidation judgments** — Scope of consolidation and reported assets/liabilities - Revenue is concentrated in a few supply contracts, so timing changes can move quarterly results - Transition Services Agreement expiration with LeMaitre reduces future revenue visibility - Australian R&D tax incentives create variable other income tied to qualifying spend - R&D expense recognition drives losses and can rise sharply during trial preparation - Lease commitments affect balance sheet liabilities and cash needs - VIE consolidation requires judgment over control and exposure to losses --- *Last updated: 2026-08-11T04:46:20.989874+00:00*